^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGF overexpression

i
Other names: EGF, Epidermal Growth Factor, HOMG4, Beta-Urogastrone
Entrez ID:
Related biomarkers:
8ms
The tyrosine kinase inhibitor Gefitinib reduces C. elegans stress-induced sleep, but not likely via LET-23/EGFR inhibition. (PubMed, MicroPubl Biol)
We show that Gefitinib disrupts C. elegans stress-induced sleep (SIS) but does not impact EGF overexpression-induced sleep nor vulva induction. These findings indicate that Gefitinib does not interfere with LET-23 signaling and impairs SIS through an off-target mechanism.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGF overexpression
|
gefitinib
1year
GRP78 is Overexpressed in Non-small Cell Lung Cancer Tissues and is Associated with High VEGF Expression in Squamous Cell Carcinoma: A Pilot Study. (PubMed, Curr Cancer Drug Targets)
GRP78 overexpression was revealed in most of the investigated samples. The positive association between VEGF and GRP78 may indicate the proangiogenic role of GRP78 in lung cancer. Moreover, the positive association between VEGF and CD31 expression levels suggests that VEGF may cooperate with CD31 to promote angiogenesis in NSCLC.
Journal
|
VEGFA (Vascular endothelial growth factor A) • CD31 (Platelet and endothelial cell adhesion molecule 1) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
VEGFA overexpression • CD31 expression • VEGFA expression • EGF overexpression • VASH2 overexpression
over1year
Antibody-fragment based immunotherapeutic approaches for medulloblastoma and rhabdomyosarcoma (ESMO 2023)
The IT and BKM-120 were used in the BBB-model showing preliminary results of permeability. Conclusions Targeted innovative scFv-based immunotherapy as highly specific and less immunogenic therapy for MB or RMS was established, also as combination therapy approach.
Tumor mutational burden • IO biomarker
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • ANXA5 (Annexin A5) • SHH (Sonic Hedgehog Signaling Molecule)
|
EGFR mutation • PIK3CA mutation • EGFR overexpression • EGF overexpression
|
buparlisib (AN2025)
over1year
Potential prognostic and immunotherapeutic value of calponin 1: A pan-cancer analysis. (PubMed, Front Pharmacol)
Our study has shown that CNN1 expression is aberrantly elevated in various cancers and positively correlates with angiogenesis and the immune checkpoint, contributing to cancer progression and poor prognosis. These results suggest that CNN1 could serve as a promising candidate for pan-cancer immunotherapy.
Journal • IO biomarker • Pan tumor
|
TNFRSF14 (TNF Receptor Superfamily Member 14) • TNFRSF18 (TNF Receptor Superfamily Member 18) • NRP1 (Neuropilin 1)
|
VEGFA overexpression • VEGFA expression • EGF overexpression • VASH2 overexpression
almost2years
Clinical application study on miR-98-5p as a prognostic biomarker in hepatocellular carcinoma. (PubMed, Clin Res Hepatol Gastroenterol)
MiR-98-5p can target the down-regulating HBEGF gene. In addition, miR-98-5p combined with MRI data is of crucial guiding value in assessing the prognosis of patients with HCC in the clinic.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • EGF (Epidermal growth factor) • TGFB1 (Transforming Growth Factor Beta 1) • MIR98 (MicroRNA 98)
|
EGF overexpression
almost2years
Autocrine EGF and TGF-α promote primary and acquired resistance to ALK/c-Met kinase inhibitors in non-small-cell lung cancer. (PubMed, Pharmacol Res Perspect)
Clinically, NSCLC patients with high expression of EGF and TGF-α developed primary resistance to crizotinib. Furthermore, combined treatment with gefitinib circumvented EGF- and TGF-α-mediated primary and acquired resistance to TAE684/SGX-523. Taken together, these results suggested increased autocrine EGF and TGF-α conferred primary and acquired resistance to ALK/c-Met kinase inhibitors in NSCLC.
Preclinical • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • TGFA (Transforming Growth Factor Alpha)
|
EGF overexpression
|
Xalkori (crizotinib) • gefitinib • TAE-684 • SGX523
2years
Low-dose arsenite causes overexpression of EGF, TGFα, and HSP90 through Trx1-TXNIP-NLRP3 axis mediated signaling pathways in the human bladder epithelial cells. (PubMed, Ecotoxicol Environ Saf)
Furthermore, our results also showed that the Trx1-TXNIP-NLRP3 axis was activated in arsenite-treated cells, and played a pivotal role in activation of the signaling pathways involved in overexpression of EGF, TGFα, and HSP90. In conclusion, the Trx1-TXNIP-NLRP3 axis might be activated by arsenite-induced redox imbalance in bladder uroepithelial cells, and mediate the activation of signaling pathways involved in overexpression of EGF, TGFα, and HSP90.
Journal
|
EGF (Epidermal growth factor) • NLRP3 (NLR Family Pyrin Domain Containing 3) • TGFA (Transforming Growth Factor Alpha) • TXNIP (Thioredoxin Interacting Protein) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
EGF overexpression
over2years
Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment. (PubMed, Front Cell Dev Biol)
Since proteins encoded by the four genes are all localized in the extracellular matrix or interact within the extracellular compartment, we propose that cellular interactions and communications are important during the persister stage before the acquisition of chemo-resistance. Thus, persisters might be a new therapeutically relevant target in GBM.
Journal
|
CHI3L1 (Chitinase 3-like 1) • EGF (Epidermal growth factor) • FAT2 (FAT Atypical Cadherin 2)
|
EGF overexpression
|
temozolomide
over2years
Does VEGF Expression Correlate with Lymphatic Metastasis in Breast Cancer? (PubMed, FASEB J)
VEGF expression is high in most tumors. There is significant association between LVI & lymph vessels detection as studied by D II 40 expression and VEGF expression. Further studies in clinical settings are essential before incorporating VEGF expression for prognostication and customized patient care.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • VEGFA (Vascular endothelial growth factor A)
|
VEGFA overexpression • VEGFA expression • EGF overexpression • VASH2 overexpression
over2years
The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis. (PubMed, J Orthop Surg Res)
Our meta-analysis findings suggest that elevated VEGF expression may be a predictive biomarker for poor prognosis and adverse clinicopathological characteristics in patients with osteosarcoma.
Retrospective data • Review • Journal
|
VEGFA (Vascular endothelial growth factor A)
|
VEGFA overexpression • VEGFA expression • EGF overexpression • VASH2 overexpression
almost3years
Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy. (PubMed, Carbohydr Polym)
Partial carboxylation of chitosan coated on MSNs allowed for a greater release of drug in a shorter duration of time while retaining pH-responsiveness and endo/lysosomal escape ability. Overall, the coating of carboxylated-chitosan over MSNs enabled tunable drug release kinetics, conjugation of aptamers (targeting agents), and endo/lysosomal escape which together significantly enhanced the efficacy of the developed drug delivery system.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 overexpression • EGFR overexpression • EGF overexpression